Why medical cannabis prescriptions are still limited on the NHS
Cannabis based medicines became legal for specialist prescription in the UK in 2018. Despite this change, access through the NHS remains relatively limited, which has led many patients to question why prescriptions are still uncommon within the public healthcare system.
Understanding the reasons behind this helps explain how medical cannabis currently fits within the wider UK healthcare framework.
Evidence and Clinical Guidelines
One of the main reasons for limited NHS prescribing is the current evidence base. Many cannabis based medicines are considered unlicensed in the UK, meaning they have not yet gone through the same large scale clinical trials required for most routinely prescribed medicines.
NHS treatment guidelines are largely based on strong clinical evidence from controlled studies. Where that evidence is still developing, prescribing may be restricted until further research becomes available.
This cautious approach is intended to ensure that treatments recommended through the NHS have well established safety and effectiveness data.
NICE Recommendations
The National Institute for Health and Care Excellence (NICE) provides guidance on which treatments should be used within the NHS.
At present, NICE guidance supports limited use of certain cannabis based medicines for specific conditions, including:
• severe treatment resistant epilepsy
• chemotherapy related nausea and vomiting
• spasticity associated with multiple sclerosis
Outside these situations, clinicians may be less likely to prescribe cannabis based medicines within the NHS.
Prescribing Responsibilities
Another factor is that prescribing cannabis based medicines requires specialist clinical oversight. In the UK, only doctors on the General Medical Council specialist register are able to initiate these prescriptions.
Because NHS specialists often work within structured treatment pathways and guideline based care, they may be cautious about prescribing medicines that fall outside established protocols.
Developing Clinical Experience
Medical cannabis is still a relatively new area of prescribing within the UK healthcare system. As more clinicians gain experience and more research becomes available, prescribing practices may continue to evolve.
Real world data collected through specialist services may also contribute to future understanding of how these medicines can be used safely and effectively.
Access Through Specialist Clinics
While NHS access remains limited, patients may sometimes explore treatment through specialist clinics.
Clinics such as Keltoi Clinic provide consultations where clinicians review medical history, discuss symptoms, and assess whether cannabis based treatment may be appropriate.
If treatment is prescribed, medicines are dispensed through licensed pharmacies and patients are usually reviewed periodically to monitor progress.
Conclusion
Although cannabis based medicines are legally available in the UK, NHS prescribing remains cautious due to evolving clinical evidence and existing treatment guidelines.
As research continues and clinical understanding develops, the role of cannabis based medicines within healthcare may become clearer over time.
Information provided for general guidance only. Individual suitability is assessed by a clinician.